Coultreon Biopharma
coultreon.com
Actively hiring
Immunology & Inflammation Therapeutics
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Backers
1
Sofinnova Investments
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Founders and leadersfrom filings, registers and the company's site
Pierre RaboissonDirectorscompany's site
Backed byfrom the funds' portfolios and accelerator catalogs
Sofinnova Investments Similar startupsby what they do, their industry and backers
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell…
Committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline…
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling…
On a mission to transform the future of autoimmune care. Developing innovative therapies with the potential to redefine the standard of…
News
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
Nate Massari's business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis...
Read more
Report
Coultreon Biopharma BV: Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
Nate Massari's business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn's disease, will support the advancement of Coultreon's
Read more
Report
Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
Dr. Charuworn's extensive immunology drug development experience will help accelerate the clinical development of Coultreon's first-in-class SIK3 inhibitor COL-5671
Read more
Report
Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
Dr. Charuworn's extensive immunology drug development experience will help accelerate the clinical development of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026. Coultreon Biopharma, a clinical-stage biotechnology comp
Read more
Report
Coultreon Biopharma BV: Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
Dr. Charuworn's extensive immunology drug development experience will help accelerate the clinical development of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026.
Read more
Report
Pro access
Upgrade to see all 8 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Pierre Raboisson
Directors
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Leuven
Belgium
Regional office
50-200 est. staff
Gaston Geenslaan 3, Leuven, 3001, BE